Atlas FDA

RESTYLANE SILK SPHAL

FDA premarket approval P040024/S072 · decided 2014-06-13

Approval details

PMA number
P040024
Supplement
S072
Supplement type
Panel Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
RESTYLANE SILK SPHAL
Generic name
Implant, dermal, for aesthetic use
Applicant
Q-Med AB
Date received
2013-10-21
Decision date
2014-06-13
Days to decision
235 days
Decision code
APPR
Product code
LMH
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Uppsala
Statement
APPROVAL FOR RESTYLANE SILK. THIS DEVICE IS INDICATED FOR SUBMUCOSAL IMPLANTATION FOR LIP AUGMENTATION AND DERMAL IMPLANTATION FOR CORRECTION OF PERIORAL RHYTIDS IN PATIENTS OVER THE AGE OF 21.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.